Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Targeting the Microenvironment in High Grade Serous Ovarian Cancer.

Nwani NG, Sima LE, Nieves-Neira W, Matei D.

Cancers (Basel). 2018 Aug 10;10(8). pii: E266. doi: 10.3390/cancers10080266. Review.

2.

Phase I trial of selenium plus chemotherapy in gynecologic cancers.

Song M, Kumaran MN, Gounder M, Gibbon DG, Nieves-Neira W, Vaidya A, Hellmann M, Kane MP, Buckley B, Shih W, Caffrey PB, Frenkel GD, Rodriguez-Rodriguez L.

Gynecol Oncol. 2018 Sep;150(3):478-486. doi: 10.1016/j.ygyno.2018.07.001. Epub 2018 Jul 29.

3.

Hormonal strategies in gynecologic cancer: Bridging biology and therapy.

Nieves-Neira W, Kim JJ, Matei D.

Gynecol Oncol. 2018 Aug;150(2):207-210. doi: 10.1016/j.ygyno.2018.06.005. Epub 2018 Jun 20. No abstract available.

PMID:
29933928
4.

Survival Disparities by Hospital Volume Among American Women With Gynecologic Cancers.

Seagle BL, Strohl AE, Dandapani M, Nieves-Neira W, Shahabi S.

JCO Clin Cancer Inform. 2017 Nov;1:1-15. doi: 10.1200/CCI.16.00053.

5.

The Hispanic Paradox in endometrial cancer: A National Cancer Database study.

Malagon-Blackwell EM, Seagle BL, Nieves-Neira W, Shahabi S.

Gynecol Oncol. 2017 Aug;146(2):351-358. doi: 10.1016/j.ygyno.2017.05.026. Epub 2017 May 23.

PMID:
28549815
6.

Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors.

Garcia-Soto AE, Schreiber T, Strbo N, Ganjei-Azar P, Miao F, Koru-Sengul T, Simpkins F, Nieves-Neira W, Lucci J 3rd, Podack ER.

Gynecol Oncol. 2017 Jun;145(3):413-419. doi: 10.1016/j.ygyno.2017.03.512. Epub 2017 Apr 6.

PMID:
28392126
7.

Association of Lymph Node Count and Overall Survival in Node-Negative Endometrial Cancers.

Seagle BL, Gilchrist-Scott D, Graves S, Strohl AE, Nieves-Neira W, Shahabi S.

JCO Clin Cancer Inform. 2017;1. doi: 10.1200/CCI.16.00064. Epub 2017 Aug 8.

8.

Survival After Pelvic Exenteration for Cervical Cancer: A National Cancer Database Study.

Graves S, Seagle BL, Strohl AE, Shahabi S, Nieves-Neira W.

Int J Gynecol Cancer. 2017 Feb;27(2):390-395. doi: 10.1097/IGC.0000000000000884.

PMID:
27984375
9.

Chemotherapy delay after primary debulking surgery for ovarian cancer.

Seagle BL, Butler SK, Strohl AE, Nieves-Neira W, Shahabi S.

Gynecol Oncol. 2017 Feb;144(2):260-265. doi: 10.1016/j.ygyno.2016.11.022. Epub 2016 Nov 29.

PMID:
27908531
10.

Survival after pelvic exenteration for uterine malignancy: A National Cancer Data Base study.

Seagle BL, Dayno M, Strohl AE, Graves S, Nieves-Neira W, Shahabi S.

Gynecol Oncol. 2016 Dec;143(3):472-478. doi: 10.1016/j.ygyno.2016.10.018. Epub 2016 Oct 17.

PMID:
27760707
11.

Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.

Garcia-Soto AE, Java JJ, Nieves Neira W, Pearson JM, Cohn DE, Lele SB, Tewari KS, Walker JL, Alvarez Secord A, Armstrong DK, Copeland LJ.

Gynecol Oncol. 2016 Dec;143(3):484-489. doi: 10.1016/j.ygyno.2016.10.003. Epub 2016 Oct 7.

12.

Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: A National Cancer Data Base study.

Rydzewski NR, Strohl AE, Donnelly ED, Kanis MJ, Lurain JR, Nieves-Neira W, Strauss JB.

Cancer. 2016 Dec 1;122(23):3724-3731. doi: 10.1002/cncr.30228. Epub 2016 Aug 10.

13.

Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.

Song M, DiPaola RS, Cracchiolo BM, Gibbon DG, Hellmann M, Nieves-Neira W, Vaidya A, Wagreich AR, Shih WJ, Rodriguez-Rodriguez L.

Int J Gynecol Cancer. 2014 Nov;24(9):1636-41. doi: 10.1097/IGC.0000000000000258.

14.

Taxanes in combination with biologic agents for ovarian and breast cancers.

Karki R, Seagle BL, Nieves-Neira W, Shahabi S.

Anticancer Drugs. 2014 May;25(5):536-54. doi: 10.1097/CAD.0000000000000056. Review.

PMID:
24300916
15.

Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.

Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P, Villunger A, Adams JM, White E.

Cancer Cell. 2005 Mar;7(3):227-38.

16.

Gynecologic malignancies in older women.

Mirhashemi R, Nieves-Neira W, Averette HE.

Oncology (Williston Park). 2001 May;15(5):580-6; discussion 592-4, 597-8. Review.

17.

Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells.

Shao RG, Cao CX, Nieves-Neira W, Dimanche-Boitrel MT, Solary E, Pommier Y.

Oncogene. 2001 Apr 5;20(15):1852-9.

18.

Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139.

Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM.

J Biol Chem. 2000 Mar 31;275(13):9390-5.

19.

DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells.

Nieves-Neira W, Rivera MI, Kohlhagen G, Hursey ML, Pourquier P, Sausville EA, Pommier Y.

Mol Pharmacol. 1999 Sep;56(3):478-84.

PMID:
10462535
21.

Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells.

Hiraoka W, Vazquez N, Nieves-Neira W, Chanock SJ, Pommier Y.

J Clin Invest. 1998 Dec 1;102(11):1961-8.

22.

Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol.

Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T, Losiewicz MD, Pommier Y, Sausville EA, Senderowicz AM.

Blood. 1998 Jan 15;91(2):458-65.

24.

Cellular resistance to camptothecins.

Pommier Y, Gupta M, Valenti M, Nieves-Neira W.

Ann N Y Acad Sci. 1996 Dec 13;803:60-73. Review. No abstract available.

PMID:
8993501
25.

S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells.

O'Connor PM, Nieves-Neira W, Kerrigan D, Bertrand R, Goldman J, Kohn KW, Pommier Y.

Cancer Commun. 1991 Aug;3(8):233-40.

PMID:
1653585

Supplemental Content

Loading ...
Support Center